(PDF) P104 Anti-Pd-1 Combination Therapy in Second or Later

P104 Anti-Pd-1 Combination Therapy in Second or Later Lines in Patients With Advanced Non Small Cell Lung Cancer

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.130

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

P013 Anti-Pd-1 Combination Therapy as Second Line Treatment or Beyond in Patients With Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer

Journal of Cancer

English

Feasibility of Continuing Crizotinib Therapy After RECIST-PD in Advanced Non-Small Cell Lung Cancer Patients With ALK/ROS-1 Mutations

Journal of Cancer

English

PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer

Medicinski podmladak

English

P3.04-21 Antibiotics Attenuate the Clinical Benefit of Anti-Pd-(L)1 Immunotherapies in Chinese Patients With Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Maintenance Therapy Improves Survival Outcomes in Patients With Advanced Non-Small Cell Lung Cancer

Respiratory Medicine

English

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer

Cancer Research

English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English